Home | Find A Doctor | Contact Us


A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of V212 in Adult Patients with Solid Tumor or Hematologic Malignancy

Principal Investigator: Anupama Goel, MD
Time frame of study: Ongoing
Location of Study:

Mount Sinai Beth Israel
St.Luke's-Mount Sinai West


Continuum Cancer Research Program
(212) 844-6286


This research study aims to test an investigational vaccine (V212), a varicella-zoster virus (VZV) vaccine in the prevention of shingles in subjects with solid tumor malignancy or hematologic tumor malignancy. This vaccine has been treated with a low dose of radiation to kill the vaccine virus. The inactivated VZV vaccine is made with one additional step that stops the virus’ ability to spread. It is possible that a very small number of virus particles may still be able to spread, and the inactivated VZV vaccine may contain a little bit of live vaccine virus.

Eligibility and Treatment Plan:

• 18 years of age or older
• Diagnosed with a solid tumor or hematologic malignancy
• Prior history of varicella or antibodies to VZV
• All female patients of childbearing potential must have a negative serum or urine pregnancy test.

Please call for more information.



Privacy Policy | Site Map
Copyright ©  Icahn School of Medicine at Mount Sinai | Mount Sinai Health System